XML 14 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 11,948,858 $ 22,604,481
Supplies for clinical trials 1,661,658 1,158,632
Other assets 767,020 797,425
Total current assets 14,377,536 24,560,538
Property and equipment, net 143,974 180,922
Supplies for clinical trials 1,067,731 1,115,657
Deposits 3,449,006 4,176,280
Deferred financing costs 228,103 48,977
Total assets 19,266,350 30,082,374
Current liabilities:    
Accounts payable 709,167 1,161,258
Accrued compensation and benefits 330,925 790,487
Accrued liabilities 601,658 317,653
Total current liabilities 1,641,750 2,269,398
CIRM liability 4,680,728 4,133,905
Warrant liability 1,063,335 1,958,775
Total liabilities 7,385,813 8,362,078
Commitments and contingencies (Note 5)
Shareholders’ equity:    
Common stock, $0.0001 par value; 249,000,000 shares authorized; 93,395,802 and 90,310,149 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively 9,340 9,031
Additional paid-in capital 96,971,853 95,849,005
Accumulated deficit (85,100,656) (74,137,740)
Total shareholders’ equity 11,880,537 21,720,296
Total liabilities and shareholders’ equity $ 19,266,350 $ 30,082,374